COVID-19 transgenic mouse model
Services
We are ready to answer your questions and provide guidance.
SARS-Cov-2
in vitro assays
IITRI offers in vitro testing of potential antivirals against multiple relevant strains of SARS-CoV-2. We source new variants as soon as available for testing and can test the cytotoxicity of your drug as well. Below is a basic study description and design, although IITRI can tailor assays based on your needs.
- This assay looks at the 50% inhibitory concentration (IC50) of the test article (TA) or serum against SARS-CoV-2.
- Briefly, cells are plated in a 96 well plate. Serial dilutions (i.e. 1:2, 1:3 or 1:10) of TA or sera are mixed with equal volumes of the virus at a low MOI (i.e. 0.005 TCID50/cell). The virus:TA or sera mixture is added to the cells. The cells are washed and overlaid with media with or without the test article.
- Other variations are possible to sponsor’s specific requests (TA addition prior to virus inoculation (pretreatment) or after virus inoculation (post treatment).
- This assay looks at the extent of viral replication measured and expressed as a percentage of virus controls (set to 100% virus replication) and cell controls (set to 0% or background). Virus Controls and Cell Controls are loaded in each plate.
- 48 hours after virus inoculation, cells are fixed and detected with coronavirus specific monoclonal antibody.
Contact us today to learn more and discuss how we can partner for infectious disease in vitro assays and animal studies.